Molecular Partners Proposes Biotech Business Development Veteran Clare Fisher for Board Election

summarizeSummary

Molecular Partners announced the nomination of Clare Fisher, a seasoned biotech business development executive, for election to its Board of Directors at the upcoming Annual General Meeting, while long-serving director Steven H. Holtzman will not seek re-election.

check_boxKey Events

• New Board Nominee Proposed

  Clare Fisher has been proposed for election as a new member of the Board of Directors at the upcoming Annual General Meeting.

• Extensive Biotech Experience

  Clare Fisher brings over two decades of leadership experience in business and corporate development, mergers and acquisitions, and strategy from various biotech and pharmaceutical companies, including BeOne Medicines, Kaleido, Shire plc, and Cubist Pharmaceuticals.

• Long-Serving Director Departs

  Steven H. Holtzman will not stand for re-election after 12 years of service on the Board of Directors, with the company expressing gratitude for his contributions.

• Annual General Meeting Scheduled

  The Annual General Meeting 2026 is scheduled to be held on Tuesday, April 14, 2026.

auto_awesomeAnalysis

Molecular Partners is strengthening its Board of Directors with the proposed election of Clare Fisher, a highly experienced executive in biotech business development and M&A. Her background at companies like BeOne Medicines, Kaleido, Shire, and Cubist Pharmaceuticals brings critical expertise for a clinical-stage biotech company focused on partnerships and pipeline expansion. This strategic addition is a positive development for the company's growth trajectory. The departure of long-serving director Steven H. Holtzman appears to be an amicable transition, with the company expressing gratitude for his 12 years of service.